© Tim Boyle
/ AFP
|
The
humble Aspirin pill may become the next revolution in cancer treatment,
doubling the life expectancy of cancer patients, according to major new
research by Dutch scientists.
Some
14,000 patients in the Netherlands participated in the study, having been
diagnosed with gastrointestinal cancer from 1998 until 2011.
Those
of them who took aspirin subsequently had a “significant” survival benefit: in
the four-year follow-up period, those who took aspirin were two twice as likely
to be alive.
Trial
co-ordinator Dr Martine Frouws, from Leiden University in the Netherlands,
presented the results at the 2015 European Cancer Congress in Vienna and
explained why the study could lead to a revolutionary outcome for those
suffering from cancer.
"Now
we would like to analyze tumor material from these patients to try and discover
which ones would benefit from aspirin treatment... Given that aspirin is a
cheap, off-patent drug with relatively few side-effects, this will have a great
impact on healthcare systems as well as patients,” Dr Frouws said.
The
study included most frequent gastrointestinal cancer types, such as colon,
rectum, and oesophagus cancer. In a way, it also makes the research
unprecedented: previously, only one type of cancer, usually colorectal, was
studied, according to the official press release.
Currently,
researchers are carrying out another cancer and aspirin-related study in a
multicenter, randomized, placebo-controlled trial that is looking into the
effect of a daily dose of 80 mg aspirin on elderly patients with colon cancer
in The Netherlands.
Why
does aspirin help, then? The researchers think it could be due to its
antiplatelet effect: platelets are a blood component which stops bleeding by
clumping and clogging blood vessel injuries, and some tumour cells are believed
to hide themselves from the immune system with the help of the platelets that
surround them.
Aspirin
inhibits platelets, thus letting the immune system to recognise tumor cells and
destroy them.
“Medical
research is focusing more and more on personalised medicine, but many
personalized treatments are expensive and only useful in small populations. We
believe that our research shows quite the opposite – it demonstrates the
considerable benefit of a cheap, well-established and easily obtainable drug in
a larger group of patients, while still targeting the treatment to a specific
individual,” Dr Frouws said.
"In
total, 30.5 percent of patients used aspirin pre-diagnosis, 8.3 percent were
solely post-diagnosis users, and 61.1 percent had not taken aspirin at all. The
commonest sites for tumours were colon (42.8 percent of patients), rectum (25.4
percent), and oesophagus (10.2 percent). Median follow-up time for all patients
was 48.6 months, with 28 percent of patients surviving for at least five
years," the press release by the Dutch scientists reads.
The
researchers’ colleagues, who didn’t participate in the research, were very
optimistic about the results.
“Aspirin
may serve as the magic bullet because it can target and prevent ischaemic heart
disease, cancer and Alzheimer’s disease, the three major health catastrophes in
the third millennium,” ESMO [European Society for Medical Oncology]
spokesperson, Professor Nadir Arber, MD, Head of the Integrated Cancer
Prevention Center in Tel Aviv, Israel, said.
“We have good evidence that
the frequent use of aspirin in the population can prevent some cases of
colorectal cancer. Now, Dr Frouws and colleagues show that in over 13,000
patients who were diagnosed with a gastrointestinal cancer, aspirin also
improved survival compared with those who did not use it. With more and more
data to support the beneficial role of aspirin, we must consider whether we
should recommend it to a wider public,” Professor Peter Naredi, the European
Cancer Organization scientific co-chair of the Congress, added.
Daily Aspirin Dose Draws Back
Obesity-Related Cancer Risks — Study
Simple
aspirin could be a powerful weapon for overweight people to reduce any
additional risks of developing colon cancer stemming from a genetic
predisposition called Lynch Syndrome, a new international study has revealed.
The
research led by Newcastle University’s Professor Sir John Burn followed nearly
1,000 patients in 43 medical centers across 16 countries, who suffer from the
syndrome which affects genes responsible for detecting and repairing damage in
DNA.
The
decade-long study, published in the Journal of Clinical Oncology,
revealed that being overweight more than doubles the risk of developing cancer
in patients with Lynch Syndrome.
Two
sets of patients who either took 600mg of aspirin daily for two years or a
placebo, simulated medically ineffectual treatment. The results of the 937
patients who took part in the study were reviewed ten years later.
“This
is important for people with Lynch Syndrome, but affects the rest of us too.
Lots of people struggle with their weight and this suggests the extra cancer
risk can be cancelled by taking an aspirin,” Burn said.
Researchers
discovered that 55 patients with the syndrome had eventually developed colon
cancers – but those who were overweight were 2.75 times as likely to develop
this type of a disease.
However,
for the patients who were taking aspirin, the risk remained the same regardless
of their body mass.
“What
is surprising is that even in people with a genetic predisposition for cancer,
obesity is also a driver of the disease. Indeed, the obesity-associated risk
was twice as great for people with Lynch Syndrome as for the general
population,” said Professor John Mathers, Professor of Human Nutrition at
Newcastle University.
In
addition scientists discovered that every extra unit of body mass index (BMI)
above healthy threshold increased the risk of cancer by 7 percent. In order to
fight the potential risk of the decease, besides taking aspirin, researchers
urged their patients to try and lose weight first as constant use of aspirin
can cause stomach ulcers.
“Our
study suggests that the daily aspirin dose of 600 mg per day removed the
majority of the increased risk associated with higher BMI. However, this needs
to be shown in a further study to confirm the extent of the protective power of
the aspirin with respect to BMI,” said Professor Tim Bishop from the University
of Leeds.
Now
the researchers are in the process of recruiting 3,000 more patients for a
follow-up study on the effects of different doses of aspirin for Lynch Syndrome
patients. Scientists believe that aspirin tackles the root mechanism by
changing the cells which are predisposed to become cancerous and want to test
this hypothesis further.
“We
may be seeing a mechanism in humans whereby aspirin is encouraging genetically
damaged stem cells to undergo programmed cell death, this would have an impact
on cancer,” says Burns.